- Targets
- 6
- Filings
- 8
- Median premium
- —
- First filing
- Jan 10, 2018
- Latest filing
- Oct 1, 2025
Targets
| Company | Score before deal | Score now | Filings | Latest |
|---|---|---|---|---|
| 89bio, Inc. | — | — | 2 | Oct 1, 2025 |
| Poseida Therapeutics, Inc. | — | — | 1 | Dec 9, 2024 |
| GenMark Diagnostics, Inc. | — | — | 1 | Mar 25, 2021 |
| Spark Therapeutics, Inc. | — | — | 1 | Mar 7, 2019 |
| Foundation Medicine, Inc. | — | — | 2 | Jul 2, 2018 |
| Ignyta, Inc. | — | — | 1 | Jan 10, 2018 |
Deal filings
| Filed | Company | Form | Price | Premium |
|---|---|---|---|---|
| Oct 1, 2025 | 89bio, Inc. | SC TO-T | — | — |
| Sep 18, 2025 | 89bio, Inc. | 8-K | — | — |
| Dec 9, 2024 | Poseida Therapeutics, Inc. | SC TO-T | — | — |
| Mar 25, 2021 | GenMark Diagnostics, Inc. | SC TO-T | — | — |
| Mar 7, 2019 | Spark Therapeutics, Inc. | SC TO-T | — | — |
| Jul 2, 2018 | Foundation Medicine, Inc. | SC 13E3 | — | — |
| Jul 2, 2018 | Foundation Medicine, Inc. | SC TO-T | — | — |
| Jan 10, 2018 | Ignyta, Inc. | SC TO-T | — | — |